E_DEPRECATED Error in file »functions_general.php« at line 301: Function utf8_encode() is deprecated Moberg - ProfileE_DEPRECATED Error in file »functions_general.php« at line 348: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 301: Function utf8_encode() is deprecated

PharmiNews

Directory of Pharma Companies and News

Company Profile

E_DEPRECATED Error in file »functions_general.php« at line 301: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 357: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 375: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 400: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 317: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 292: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 284: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 348: Function utf8_encode() is deprecated

Moberg

E_DEPRECATED Error in file »functions_general.php« at line 326: Function utf8_encode() is deprecated
E_DEPRECATED Error in file »functions_general.php« at line 326: Function utf8_encode() is deprecated Moberg logoE_DEPRECATED Error in file »functions_general.php« at line 186: Function utf8_encode() is deprecated
Category
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®, Domeboro®and Fiber Choice®. Kerasal Nail® (Emtrix®, Zanmira® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).
Keywords:
Finance Jobs News Website
E_DEPRECATED Error in file »company-code.php« at line 190: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 301: Function utf8_encode() is deprecated

Moberg News

DateNews
2020-02-11Moberg Pharma AB Interim report October - December 2019
2020-02-04Moberg Pharma’s Interim report to be published on February 11 - Invitation to teleconference
2020-01-22Expert evaluation clarifies Phase 3 results and provides strong support for MOB-015
2020-01-14The Swedish Tax Agency has published a notification on distribution of the acquisition cost of shares due to the redempt...
2019-12-12Moberg Pharma comments on the results of the North American Phase 3 study with MOB-015
2019-12-09Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis
2019-11-29Reclassification of series B shares in Moberg Pharma AB (publ)
2019-11-19Moberg Pharma AB Interim report July - September 2019
2019-11-12Moberg Pharma’s Interim report for July - September 2019 to be published on November 19 - Invitation to teleconference
2019-10-30Bulletin from Moberg Pharma’s AGM on October 30th , 2019
Brought to you by PharmiWeb.com - Latest Jobs in Pharma